You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Section: EXTERNAL EYE DISEASES<br />
Chairperson: P.A. Asbell, USA<br />
<strong>ISOPT</strong> <strong>Program</strong><br />
Dry Eye Disease / Biomarkers for Ocular Surface Disease<br />
Proteomics for the Diagnosis of Ocular Surface Disease<br />
R. Beuerman, Singapore<br />
Protein Biomarkers and Tear Film and Dry Eye Disease<br />
F. Grus, Germany<br />
Lymphocytes Detection on the Ocular Surface of Dry Eye Patients<br />
S. Barabino, Italy<br />
Impression Cytology and Dry Eye Disease<br />
P. Asbell, USA<br />
Panel Q&A<br />
All Speakers<br />
Anterior Segment Imaging / Devices<br />
Anterior Segment OCT<br />
J.S. Mehta, Singapore<br />
Imaging and In Vivo Confocal Microscopy for Assesing Inflammatory Ocular Surface<br />
Diseases<br />
C.Baudouin, France<br />
Confocal Microscopy: New Development<br />
R. Beuerman, Singapore<br />
DSAEK ‐ Cornea Insertion Devices<br />
P. Asbell, USA<br />
OCT and Tearfilm<br />
L. Fan, China<br />
Panel Q&A<br />
All Speakers
Meibomian Gland Dysfunction<br />
Tear Film & Ocular Surface Society<br />
Session Moderators: K. Nichols, USA, P. Asbell, USA & D. Sullivan, USA<br />
Introduction<br />
K. Nichols, USA<br />
Definition and Classification of Meibomian Gland Dysfunction (MGD)<br />
K. Nichols, USA<br />
Anatomy, Physiology and Pathophysiology of the Meibomian Gland<br />
D. Sullivan, USA<br />
Tear Film Lipids, and Lipid‐Protein Interactions, in Health and Disease<br />
D. Sullivan, USA<br />
Epidemiology of, and Associated Risk Factors for, MGD<br />
K. Nichols, USA<br />
Evaluation, Diagnosis and Grading of Severity of MGD<br />
M. Rolando, Italy<br />
Management and Therapy of MGD<br />
C. Baudouin, France<br />
Design and Conduct of Clinical Trials<br />
P. Asbell, USA<br />
Cases: Discussion<br />
Post Lasik Dry Eye<br />
Presented by:<br />
P. Asbell, USA<br />
R. Beuerman, Singapore<br />
I. Barequet, Israel<br />
M.K. Kim, S. Korea
Section: INFLAMMATION AND INFECTION<br />
Chairperson: R. Neumann, Israel<br />
Ocular Infectious Uveitis<br />
Ocular Tuberculosis<br />
P. Choopong, Thailand<br />
Ocular Toxoplasmosis<br />
TBA<br />
Emerging Ocular Infections and Their Therapy<br />
TBA<br />
Posterior Uveitis<br />
Management of Posterior Uveitis: Adapting Therapy to Specific Diagnosis<br />
VKH, Behcet's, BSCR, Sarcoidosis, Idiopathic<br />
Panel: E. Letko, USA, M. Kramer, Israel, H. Uy, Philippines, C. Deuter, Germany<br />
Managing Uveitis in Children<br />
Immunosuppressive Agents in Children<br />
The Effect of Steroids in Children<br />
Biologic Agents in Children<br />
Panel: D. Chu, USA, E. Letko, USA, C. Deuter, Germany, M. Kramer, Israel<br />
Ocular Infection<br />
Chairperson: I. Barequet, Israel<br />
The Evaluation of Antibiotics in the Prophylaxis or Treatment of Endophthalmitis<br />
Using Animal Model<br />
T, Suzuki, USA<br />
TBA<br />
C.K. Joo, South Korea<br />
Bacteriologic Profile of the Conjunctiva and Susceptibility to Fluoroquinolones<br />
N. Maeda, Japan<br />
Infection of Ocular Surface (Corneal Ulcers) in Vietnam National Institute of<br />
Ophthalmology<br />
P. Thi Khanh Van, Vietnam<br />
Antibacterial Prophylaxis in Anterior Segment Surgery<br />
I. Barequet, Israel
UVA Light and Riboflavin Application for Infectious Keratitis<br />
E. Letko, USA<br />
TRUST: Tracking Resistance of Ocular Infections<br />
P. Asbell, USA<br />
Section: GLAUCOMA<br />
Chairpersons: J. Jonas, Germany & X. Zhang, China<br />
New Drug Classes on the Horizon for Glaucoma Therapy<br />
Different Modalities of Ocular Drug Delivery for Glaucoma<br />
T. Wong, Singapore<br />
Medical Treatment for Angle Closure Glaucoma<br />
S. Sawaguchi, Japan<br />
Drug and Technique: Wound Modulation in Glaucoma Surgery<br />
K. Nagpal, India<br />
Statins and Glaucoma<br />
D. Leung, Hong Kong<br />
New Devices in Glaucoma Therapies<br />
Anterior Segment OCT in Glaucoma<br />
M. He, China<br />
Applications of Ocular Response Analyzer in Normal Tension Glaucoma<br />
D. Leung, Hong Kong<br />
The Use of the ExPress Implant in Asian Eyes<br />
H.C. Ling, Singapore<br />
Selective Laser Trabeculoplasty in the Treatment of POAG<br />
T. Wang, China<br />
Glaucoma Screening With a Self‐Operated, Inexpensive, Comprehensive Instrument:<br />
Can It Be Done?<br />
A. Walsh, USA<br />
Tube vs. Trabeculectomy Study<br />
TBA<br />
Latest Thinking on Mechanisms in Glaucoma<br />
TRP Channel: A Potential Target for Human Glaucoma<br />
X. Zhang, China<br />
The Activation and Modulation of Astrocyte in Glaucoma<br />
W. Jihong, China
Correlation in Genotype and Phenotype in POAG<br />
J. Ge, China<br />
Population Based Studies and Vascular Risk Factors<br />
A. Harris, USA<br />
Glaucoma: Just Another Optic Neuropathy<br />
TBA<br />
R. Ellis‐Behnke, Hong Kong<br />
Axon Injury and Axon Therapy<br />
L. Levin, USA<br />
Physical Therapy and Neuroprotection for Glaucoma<br />
N. Wang, China<br />
Neuroprotection<br />
Neuroprotective Effects of CNP on Glaucomatous Neuropathy<br />
L. Xuyang, China<br />
Neuroprotective Effects of Agmatine on Various Oxidative Stressed Neurons<br />
S. Hong, S. Korea<br />
Protective Effect of Gross Saponin of Tribulus Terrestris (GSTT) on Retinal Ganglion<br />
Cells and Optic Nerve in Rabbits with Chronic Intraocular Hypertension<br />
L. Huang, China<br />
New Pathways in Neuroprotection<br />
C. Zhang, China<br />
TBA<br />
R. Ellis‐Behnke, Hong Kong<br />
Worldwide Glaucoma Economics<br />
Glaucoma Screening ‐to Increase Potential Value<br />
L. Xu, China<br />
Glaucoma Economics and Prevalence in China<br />
Z. Jialiang, China<br />
EVER Symposium<br />
Session Chair: L. Schmetterer, Austria<br />
Pathogenic Hints for Glaucoma from the Optic Nerve Head<br />
J. Jonas, Germany<br />
Autoimmunity and Glaucoma<br />
F. Grus, Germany
Impact of Long Term Use of Preservatives on the Ocular Surface<br />
C. Baudouin, France<br />
What Can We Expect from Functional OCT for Glaucoma<br />
L. Schmetterer, Austria<br />
Section: RETINA<br />
Chairperson: B.D. Kupperman, USA<br />
Dry AMD<br />
Alprostadil<br />
A. Augustin, Germany<br />
Anti‐C3<br />
C. Francois, USA<br />
Retinoids<br />
D. Saperstein, USA<br />
Complement Inhibition for AMD ‐ Overview<br />
F. Behar, France<br />
ACU‐4429‐Visual Cycle Modulator as Potential Therapy for DRY AMD<br />
N. Boman, USA<br />
AREDS 2<br />
P. Bernstein, USA<br />
Wet AMD<br />
Role of Inflammation in AMD and DR<br />
A. Augustin, Germany<br />
Lucentis versus Avastin for CNV/AMD<br />
A. Loewenstein, Israel<br />
Ozurdex Plus Lucentis for CNV<br />
B. Kuppermann, USA<br />
PDGF Plus Lucentis for CNV<br />
D. Boyer, USA<br />
POT RACE Study<br />
D. Boyer, USA<br />
DENALI/Mt BLANC/EVEREST<br />
TBA<br />
Wet AMD Panel<br />
TBA
Wet AMD Combination Therapy<br />
Triple Therapy<br />
A. Augustin, Germany<br />
Iluvien Plus Lucentis<br />
TBA<br />
Diabetic Retinopathy<br />
Role of Vitreous in DR Progression<br />
A. Gandorfer, USA<br />
Vascular Toxicity or Steroids<br />
F. Behar, France<br />
TA/Steroids for inhibition of progression of DR<br />
M. Ip, USA<br />
Macugen<br />
V. Gonzalez, France<br />
Diabetic Macular Edema<br />
Laser Plus Anti‐VEGF for DME<br />
A. Augustin, Germany<br />
Ozurdex for DME<br />
B. Kuppermann, USA<br />
Iluvien FAME for DME<br />
B. Boyer, USA<br />
Lucentis READ 2<br />
D. Do, USA<br />
VEGF Trap Phase 2<br />
D. Do, USA<br />
Laser Plus Steroids for DME<br />
F. Bandello, Italy<br />
Role of The Lallikrein‐Kinin System in Diabetic Retinopathy<br />
P. Belichard, France<br />
Lucentis RISE & RIDE<br />
TBA<br />
Macugen<br />
V. Gonzalez, USA<br />
ICo‐007, a VEGF "+" Agent for the Potential Treatment of Diabetic Macular Edema<br />
and Diabetic Retinopathy<br />
V. Gonzalez, USA
Treatments for Retinal Vein Occlusion<br />
Lucentis/Ranibizumab for Central Retinal Vein Occlusion: CRUISE<br />
A. Loewenstein, Israel<br />
Lucentis/Ranbizumab for Branch Retinal Vein Occlusion: BRAVO<br />
A. Loewenstein, Israel<br />
Ozurdex for RVO<br />
B. Kuppermann, USA<br />
SCORE CRVO Study ‐ Corticosteroid for Retinal Vein Occlusion<br />
M. Ip, USA<br />
SCORE BRVO<br />
M. Ip, USA<br />
Macugen<br />
V. Gonzalez, USA<br />
Anti‐angiogenetic Agents ‐ Other Diseases<br />
Anti‐VEGF for ROP<br />
K. Drenser, USA<br />
TBA<br />
Retinal Degeneration<br />
rh‐RdCV<br />
P. Belichard, France<br />
Cis Beta Carotene for Congenital Stationary Night Blindness<br />
Y. Rotenstreich, Israel<br />
Vitreous<br />
Microplasmin Treatment of Vitreoretinal Disease: Update on the Phase III MIVI‐<br />
TRUST <strong>Program</strong><br />
A. Gandorfer, Germany<br />
Section: BASIC SCIENCE<br />
Therapies of Retinal Neovascularization<br />
Session Moderators: A. Das, USA & J. Penn, USA<br />
TBA<br />
J. Penn, USA<br />
TBA<br />
D. Sinha, USA
TBA<br />
D. Hinton, USA<br />
TBA<br />
R. Caldwell, USA<br />
Inhibition of Diabetic Retinopathy<br />
Session Moderators: A. Das, USA & R. Kowluru, USA<br />
Diabetic Retinopathy and Mitochondrial Damage<br />
R. Kowluru, USA<br />
TBA<br />
T. Chan‐Ling, Australia<br />
TBA<br />
A. Stitt, Ireland<br />
Targeting the GAPDH Nuclear Translocation Pathway as a Potential New Strategy to<br />
Prevent Hyperglycemia‐Induced Retinal Damage<br />
S. Mohr, USA<br />
TBA<br />
R. Caldwell, USA<br />
Antioxidants<br />
Session Chair: P. Bernstein, USA<br />
Long‐Chain and Very Long‐Chain Polyunsaturated Fatty Acids in Ocular Aging and<br />
Age‐Related Macular Degeneration<br />
P. Bernstein, USA<br />
Macular Pigment Changes in Pseudophakic Eyes Quantified With Resonance Raman<br />
Spectroscopy<br />
A. Obana, Japan<br />
TBD<br />
A. Ohira, Japan<br />
Vascular Targets<br />
Session Chairs: L. Schmetterer, Austria & G. Garhoefer, Austria<br />
Role of Endothelins in Ocular Disease<br />
G. Garhoefer, Austria<br />
Retinal Circulations in Diabetes<br />
T. Nagaoka, Japan<br />
Dynamic Autoregulation<br />
L. Wang, USA
Interaction Between Intraocular Pressure and Blood Flow: Relevance for Glaucoma<br />
L. Schmetterer, Austria<br />
Gene Therapy<br />
Session Chair: C. Paterson, USA<br />
AMD Gene Therapy<br />
S. Wadsworth, USA<br />
Gene Therapy in Glaucoma<br />
CP Pang, Hong Kong<br />
Section: TCM<br />
Chairperson: X. Li, China<br />
Basic Pharmacology of TCM<br />
Session Chair: J. Duan, China<br />
Molecular Mechanism on Neuroprotection in Glaucoma Using Lycium Barbarum<br />
(Wolfberry)<br />
KF. So, Hong Kong<br />
Establishment and Evaluation of the High Throughput Screening System for<br />
Antagonistic Agents of Dry Eye Based on TGF‐β1 and Bcl‐2<br />
KH. Peng, China<br />
The Protection of the Compound Chinese Medicine MingMuWuZi on Rat Model of<br />
Light‐induced Retinal Injury<br />
HJ. Ye, China<br />
Research of Chinese Medicine QiDengMingMu Capsule Therapy Effect on STZ<br />
Induced Diabetic Rat's Blood‐Retinal Barrier and Visual Function Damage<br />
FW. Zhang, China<br />
Research of Chinese Medicine QiDenmingmu Capsule Therapy Effect on<br />
Spontaneous Diabetic Rats Retina Protein Kinase C and Vitreous Vascular Endothelial<br />
Growth Factor<br />
N. Gao, China<br />
Clinical Trials of TCM<br />
Session Chair: J. Duan, China<br />
Effects of TCM Qiming Granule on Diabetic Retinopathy: A Report of Randomized<br />
Control Multicenter Clinical Trials<br />
J. Duan, China<br />
Effect of Runmuling on Tears of the Patients With Dry Eye: A Clinical Study and<br />
Explanation of its Mechanism<br />
YL. Wang, China
Randomized Double‐Blind Placebo‐Controlled Multicenter Clinical Study of the<br />
Protective Effect of Gingko Leaf Extract on Glaucoma with IOP Controlled<br />
XJ. Lu, China<br />
Characteristics of the Corresponding Relationship of Metabolomics Profiling<br />
Between Yang Deficiency Syndrome and Diabetic Retinopathy Stage<br />
XX. Luo, China<br />
Astragalus Membranaceus and its Prescriptions in Treating Diabetic Retinopathy: a<br />
Systematic Review<br />
L. Cheng, China<br />
Section: Drug DEVELOPMENT<br />
IP and the Path to Commercialization<br />
Session Chair: R. Beuerman, Singapore<br />
TBA<br />
M. Tabiin, Singapore<br />
TBA<br />
M. Entzeroth, Singapore<br />
Reading Centers<br />
Session Chair: R. Danis, USA<br />
Non‐Standardization of Technology in Ophthalmology<br />
Y. Huang, USA<br />
Data Quality Issues in Clinical Trials<br />
M. Ip, USA<br />
Requirements and Validation of Biometry in Ophthalmic Devices<br />
M. Eydelman, USA<br />
When Do You Need a Reading Center?<br />
R. Danis, USA<br />
Drug Delivery<br />
Session Chairs: D. Tang‐Liu, USA & R. Gurny, Switzerland<br />
Encapsulated Cell Technology for Retinal Degenerative Diseases<br />
W. Tau, USA<br />
The Role of Ocular Pigmentation in the Intraocular Pressure Response to Brimonidine<br />
in Rabbits<br />
J. Burke, USA<br />
Pharmacokinetics and Pharmacodynamics Considerations in Posterior Segment Drug<br />
Delivery<br />
J.E. Lin, USA
Controlled Transscleral Drug Delivery Formulations to the Eye: Establishing New<br />
Concepts and Paradigms in Ocular Anti‐Inflammatory Therapeutics and Antibacterial<br />
Prophylaxis<br />
J. Cardillo, Brazil<br />
Toxicology<br />
Macular Pigment Changes in Pseudophakic Eyes Quantified with Resonance Raman<br />
Spectroscopy<br />
A. Obana, Japan<br />
TBA
Change language